Drugs / DNT cells
DNT cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03027102 | Aug 2017 → Dec 2024 | acute myeloid leukemia | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03027102 ↗ |
| Known as | DNT-UHN-1 | “Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia” NCT03027102 ↗ |
| Known as | Double Negative T Cells | “Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia” NCT03027102 ↗ |
| Modality | Cell therapy | “DNT cells will be collected from healthy volunteers and injected into patients.” NCT03027102 ↗ |